PEDIATRICS Vol. 75 No. 4 April 1985, pp. 667-671
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asano, Y.
Right arrow Articles by Takahashi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asano, Y.
Right arrow Articles by Takahashi, M.

Long-Term Protective Immunity of Recipients of the OKA Strain of Live Varicella Vaccine

Yoshizo Asano MD1, Takao Nagai MD1, Takao Miyata MD1, Takehiko Yazaki MD1, Shigemitsu Ito MD1, Koichi Yamanishi MD1, and Michiaki Takahashi MD1

1 From the Department of Pediatrics, Fujita-Gakuen University School of Medicine and Chukyo Hospital, Toyoake and Nagoya, Aichi, and Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

In spite of close contacts with patients who had varicella, 101 of 106 (95%) healthy and sick children (142 of 147 (97%) exposures of these children) who had received the OKA strain of live varicella vaccine 7 to 10 years earlier were protected against the disease completely. Among them, 37 of 38 (97%) vaccine recipients who received immunologic testing had varicella-zoster virus (VZV) antibodies tested by fluorescent antibody to membrane antigen method with a geometric mean titer of 1:9.3, and 37 of the 38 (97%) showed positive skin reaction to varicella-zoster virus antigen with erythema (mean diameter 13.4 mm). These findings were compared with those for 29 children who had contracted typical varicella 7 to 10 years earlier, whose seropositive rate was 100% with a geometric mean titer of 1:10.5, and 97% of whom (28/29) had positive skin reaction with mean diameter of 12.9 mm. These results indicate that the vaccine-induced protective immunity persists for approximately one decade and is almost equal to the long-term immunity following natural infection.

Key Words: varicella • live vaccine • immunity

Submitted on April 16, 1984
Accepted on May 17, 1984




This article has been cited by other articles:


Home page
 PediatricsHome page
C. T. D'Angio, P. A. Boohene, A. Mowrer, S. Audet, M. A. Menegus, D. S. Schmid, and J. A. Beeler
Measles-Mumps-Rubella and Varicella Vaccine Responses in Extremely Preterm Infants
Pediatrics, March 1, 2007; 119(3): e574 - e579.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. S. Bromage, I. M. Kaattari, P. Zwollo, and S. L. Kaattari
Plasmablast and Plasma Cell Production and Distribution in Trout Immune Tissues
J. Immunol., December 15, 2004; 173(12): 7317 - 7323.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. D. Tugwell, L. E. Lee, H. Gillette, E. M. Lorber, K. Hedberg, and P. R. Cieslak
Chickenpox Outbreak in a Highly Vaccinated School Population
Pediatrics, March 1, 2004; 113(3): 455 - 459.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
P. H. Dennehy
Active Immunization in the United States: Developments over the Past Decade
Clin. Microbiol. Rev., October 1, 2001; 14(4): 872 - 908.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S A Skull and E E L Wang
Current topic: Varicella vaccination{---}a critical review of the evidence
Arch. Dis. Child., August 1, 2001; 85(2): 83 - 90.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
D. A. Clements, J. I. Zaref, C. L. Bland, E. B. Walter, and P. M. Coplan
Partial Uptake of Varicella Vaccine and the Epidemiological Effect on Varicella Disease in 11 Day-Care Centers in North Carolina
Arch Pediatr Adolesc Med, April 1, 2001; 155(4): 455 - 461.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
N. J A Webb, M. M Fitzpatrick, D. A Hughes, T. J Brocklebank, B. A Judd, M. A Lewis, R. J Postlethwaite, P. A Smith, and G. Corbitt
Immunisation against varicella in end stage and pre-end stage renal failure
Arch. Dis. Child., February 1, 2000; 82(2): 141 - 143.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child.Home page
Y J Lim, F T Chew, A Y S Tan, and B W Lee
Risk factors for breakthrough varicella in healthy children
Arch. Dis. Child., December 1, 1998; 79(6): 478 - 480.
[Abstract] [Full Text]

Home page
 PediatricsHome page
C. E. Johnson, T. Stancin, D. Fattlar, L. P. Rome, and M. L. Kumar
A Long-term Prospective Study of Varicella Vaccine in Healthy Children
Pediatrics, November 1, 1997; 100(5): 761 - 766.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
L. F. Ross and J. D Lantos
Immunisation against chickenpox
BMJ, January 7, 1995; 310(6971): 2 - 3.
[Full Text]